The objective of the study is to assess the superiority of the everolimus-eluting stent (Endeavor Resolute®) compared with the everolimus-eluting stent (XIENCE V®) regarding uncovered stent strut segments.
The mid-term efficacy of drug-eluting stents has been well-established, but there is an ongoing debate on the potential of an increased incidence of late stent thrombosis, particularly after discontinuation of thienopyridine therapy, as well as of delayed onset of restenosis or catch-up phenomenon with permanent polymer-based DES. The extent of strut coverage with reduction of exposed thrombogenic material has been shown to be associated with the inflammatory reaction grade and with the incidence of stent thrombosis. The optical coherence tomography (OCT) is an intravascular imaging modality based on light. The principle is similar to intravascular ultrasound, but due to the much shorter wave length of light, it offers a much better resolution up to 10µm, enabling the exact determination of strut coverage, neointimal thickness, vessel size, presence of dissections, and even the presence of inflammation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
due randomization everolimus-eluting-stent will be implanted
due randomization zotarolimus-eluting-stent will be implanted
Deutsches Herzzentrum Muenchen
Munich, Bavaria, Germany
Klinikum rechts der Isar
Munich, Bavaria, Germany
Degree of stent strut coverage assessed by OCT for each visible strut segment
Time frame: 6-8 months
Percentage of malapposed strut assessed by OCT
Time frame: 6-8 months
Percentage of uncovered malapposed struts assessed by OCT
Time frame: 6-8 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.